VivoSeq
Oncology

Neuroendocrine Tumors

2

Pipeline Programs↗

27

Active Trials↗

9

Companies Involved↗

Neuroendocrine Tumors is an early-stage landscape with 2 programs across 9 companies. The most active players are Novartis, Ipsen, Eastern Cooperative Oncology Group.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

71/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalIpsen logo

Ipsen

0 programs

PreclinicalE

Eastern Cooperative Oncology Group

0 programs

PreclinicalH

Hellenic Cooperative Oncology Group

0 programs

PreclinicalM

Mateon Therapeutics

0 programs

PreclinicalAscentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 12

64cu-Dotatate

University of Wisconsin, Madison

177lu-Dotatate

University of Wisconsin, Madison

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

114

clinical trials

Completed52 · 46%
Terminated17 · 15%
Active, not recruiting13 · 11%
Recruiting12 · 11%
Unknown status11 · 10%
Withdrawn4 · 4%
Other5 · 4%

Clinical Trials

Trial Activity

114 trials

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Recruiting·GGrupo Espanol de Tumores Neuroendocrinos·Phase 3·NCT05918302·120 enrolled
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
Recruiting·MMolecular Targeting Technologies, Inc.·Phase 1·NCT05475210·9 enrolled
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Recruiting·EEmory University·Phase 1·NCT07150546·15 enrolled
Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors
Recruiting·GGrupo Espanol de Tumores Neuroendocrinos·Phase 3·NCT06878664·166 enrolled
An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors
Recruiting·—·Phase 1/2·NCT06038461·40 enrolled
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
Recruiting·UUniversity of California, San Francisco·Phase 2·NCT05746208·29 enrolled
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
Recruiting·AAadi Bioscience, Inc.·Phase 2·NCT05997056·21 enrolled
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Recruiting·—·Phase 2·NCT06472388·100 enrolled
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
Recruiting·LLund University Hospital·Phase 3·NCT05387603·300 enrolled
61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)
Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 1/2·NCT06455358·27 enrolled
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
Recruiting·PPerspective Therapeutics·Phase 1/2·NCT05636618·260 enrolled
CaboLife: A Prospective Non-Interventional Study on Effectiveness and Safety of Cabozantinib in Real-Life Setting for Previously Treated Patients With Neuroendocrine Tumour
Recruiting·Ipsen logoIpsen·N/A·NCT07314164·150 enrolled
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
Active, not recruiting·—·Phase 1·NCT06148636·24 enrolled
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
Active, not recruiting·NNicholas Fidelman, MD·Phase 2·NCT03457948·32 enrolled
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
Active, not recruiting·—·Phase 1·NCT03335670·30 enrolled
Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)